查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1609694

2024-2032 年日本蛋白质治疗市场报告（按产品（单株抗体、人类胰岛素、促红血球生成素、凝血因子、融合蛋白等）、治疗领域、功能和地区）

Japan Protein Therapeutics Market Report by Product (Monoclonal Antibodies, Human Insulin, Erythropoietin, Clotting Factors, Fusion Protein, and Others), Therapy Area, Function, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 115 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2023年日本蛋白质治疗IMARC Group规模达284亿美元。癌症、糖尿病和自体免疫疾病等慢性疾病的发生率不断上升，导致对蛋白质疗法的需求增加，以提供有针对性的有效治疗，从而推动了市场的发展。

蛋白质疗法是指利用蛋白质（通常是生物衍生分子）来预防、控製或治癒各种疾病和医疗状况的一类医学治疗方法。这些治疗性蛋白质可以包括抗体、酵素、荷尔蒙或其他在人体生物过程中发挥关键作用的功能性蛋白质。蛋白质疗法旨在针对特定的疾病机制，例如与癌细胞结合或调节免疫反应，与传统药物相比，提供高精度并减少副作用。它们通常使用生物技术（包括重组 DNA 技术）生产，并且可以透过注射、输注或其他递送方法进行施用。蛋白质疗法的例子包括用于治疗类风湿性关节炎等自体免疫疾病的单株抗体、用于糖尿病管理的胰岛素和用于血友病的凝血因子。这些疗法彻底改变了医学，为多种疾病提供了有效的治疗方法，同时透过持续的研究和开发工作不断取得进展。

日本蛋白质治疗市场趋势：

日本的蛋白质治疗市场正在蓬勃发展，这得益于推动其成长的几个关键驱动因素。首先，生物技术的进步为蛋白质药物的开发开闢了新途径。重组 DNA 技术的使用越来越多就证明了这一点，该技术可以生产具有增强特异性和功效的治疗性蛋白质。此外，癌症、糖尿病和自体免疫疾病等慢性病盛行率的上升推动了对创新治疗方案的需求。因此，製药公司正在大力投资研发，以创造针对这些疾病的新型蛋白质疗法。此外，地区人口老化是蛋白质治疗市场的重要驱动力。随着老年人口的不断增长，对能够解决与年龄相关的疾病的疗法的需求不断增加，进一步增加了对蛋白质药物的需求。此外，针对个别患者量身定制治疗方案的个人化医疗的新兴趋势预计将在预测期内推动日本的蛋白质治疗市场。

日本蛋白质治疗市场细分：

产品见解：

  • 单株抗体 (mAb)
  • 人类胰岛素
  • 促红血球生成素
  • 凝血因子
  • 融合蛋白
  • 其他的

治疗领域见解：

  • 代谢紊乱
  • 免疫系统疾病
  • 血液系统疾病
  • 癌症
  • 荷尔蒙失调
  • 遗传性疾病
  • 其他的

功能见解：

  • 酶促和调节活性
  • 特别目标活动
  • 疫苗
  • 蛋白质诊断

竞争格局：

市场研究报告也对竞争格局进行了全面分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外，也提供了所有主要公司的详细资料。

本报告回答的关键问题：

  • 日本蛋白质治疗市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对日本蛋白质治疗市场有何影响？
  • 日本蛋白质治疗市场依产品划分是怎样的？
  • 日本蛋白质治疗市场依治疗领域划分是怎么样的？
  • 日本蛋白质治疗市场依功能划分是怎样的？
  • 日本蛋白质治疗市场价值链的各个阶段是什么？
  • 日本蛋白质疗法的关键驱动因素和挑战是什么？
  • 日本蛋白质治疗市场的结构如何？
  • 日本蛋白质治疗市场的竞争程度如何？

本报告回答的关键问题：

  • 日本蛋白质治疗市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对日本蛋白质治疗市场有何影响？
  • 日本蛋白质治疗市场依产品划分是怎样的？
  • 日本蛋白质治疗市场依治疗领域划分是怎么样的？
  • 日本蛋白质治疗市场依功能划分是怎样的？
  • 日本蛋白质治疗市场价值链的各个阶段是什么？
  • 日本蛋白质疗法的关键驱动因素和挑战是什么？
  • 日本蛋白质治疗市场的结构如何？
  • 日本蛋白质治疗市场的竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：日本蛋白质治疗市场 - 简介

  • 概述
  • 市场动态
  • 产业动态
  • 竞争情报

第 5 章：日本蛋白质疗法市场格局

  • 历史与当前市场趋势（2018-2023）
  • 市场预测（2024-2032）

第 6 章：日本蛋白质治疗市场 - 细分：依产品分类

  • 单株抗体 (mAb)
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 人类胰岛素
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 促红血球生成素
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 凝血因子
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 融合蛋白
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 其他的
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 7 章：日本蛋白质治疗市场 - 细分：按治疗领域

  • 代谢紊乱
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 免疫系统疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 血液系统疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 癌症
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 荷尔蒙失调
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 遗传性疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 其他的
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 8 章：日本蛋白质治疗市场 - 细分：按功能分类

  • 酶活性和调节活性
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 特别目标活动
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 疫苗
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 蛋白质诊断
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 9 章：日本蛋白质疗法市场 - 竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳制胜策略
  • 竞争仪表板
  • 公司评估象限

第 10 章：关键参与者简介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第 11 章：日本蛋白质治疗市场 - 产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 司机
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 12 章：附录

简介目录
Product Code: SR112024A18904

Japan protein therapeutics market size reached US$ 28.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 52.7 Billion by 2032, exhibiting a growth rate (CAGR) of 6.60% during 2024-2032. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which has led to an increased demand for protein therapeutics to provide targeted and effective treatment, is driving the market.

Protein therapeutics refers to a class of medical treatments that utilize proteins, typically biologically derived molecules, to prevent, manage, or cure various diseases and medical conditions. These therapeutic proteins can include antibodies, enzymes, hormones, or other functional proteins that play crucial roles in the body's biological processes. Protein therapeutics are designed to target specific disease mechanisms, such as binding to cancer cells or modulating immune responses, offering a high degree of precision and reduced side effects compared to traditional pharmaceuticals. They are often produced using biotechnology techniques, including recombinant DNA technology, and can be administered through injections, infusions, or other delivery methods. Examples of protein therapeutics include monoclonal antibodies used to treat autoimmune diseases like rheumatoid arthritis, insulin for diabetes management, and clotting factors for hemophilia. These therapies have revolutionized medicine, providing effective treatments for a wide range of diseases while continually advancing through ongoing research and development efforts.

Japan Protein Therapeutics Market Trends:

The protein therapeutics market in Japan is thriving due to several key drivers that have propelled its growth. Firstly, advancements in biotechnology have opened up new avenues for the development of protein-based drugs. This is exemplified by the increasing use of recombinant DNA technology, which allows for the production of therapeutic proteins with enhanced specificity and efficacy. Furthermore, the rising prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, has driven the demand for innovative treatment options. As a result, pharmaceutical companies are investing heavily in R&D to create novel protein therapeutics targeting these diseases. Additionally, the aging regional population is a significant driver of the protein therapeutics market. With a growing elderly population, there is an increased need for therapies that can address age-related conditions, further bolstering the demand for protein-based drugs. Moreover, the emerging trend toward personalized medicine that tailors treatments to individual patients is expected to drive the protein therapeutics market in Japan during the forecast period.

Japan Protein Therapeutics Market Segmentation:

Product Insights:

  • Monoclonal Antibodies (mAbs)
  • Human Insulin
  • Erythropoietin
  • Clotting Factors
  • Fusion Protein
  • Others

Therapy Area Insights:

  • Metabolic Disorders
  • Immunological Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders
  • Others

Function Insights:

  • Enzymatic and Regulatory Activity
  • Special Targeting Activity
  • Vaccines
  • Protein Diagnostics

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan protein therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan protein therapeutics market?
  • What is the breakup of the Japan protein therapeutics market on the basis of product?
  • What is the breakup of the Japan protein therapeutics market on the basis of therapy area?
  • What is the breakup of the Japan protein therapeutics market on the basis of function?
  • What are the various stages in the value chain of the Japan protein therapeutics market?
  • What are the key driving factors and challenges in the Japan protein therapeutics?
  • What is the structure of the Japan protein therapeutics market and who are the key players?
  • What is the degree of competition in the Japan protein therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Protein Therapeutics Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Protein Therapeutics Market Landscape

  • 5.1 Historical and Current Market Trends (2018-2023)
  • 5.2 Market Forecast (2024-2032)

6 Japan Protein Therapeutics Market - Breakup by Product

  • 6.1 Monoclonal Antibodies (mAbs)
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2018-2023)
    • 6.1.3 Market Forecast (2024-2032)
  • 6.2 Human Insulin
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2018-2023)
    • 6.2.3 Market Forecast (2024-2032)
  • 6.3 Erythropoietin
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2018-2023)
    • 6.3.3 Market Forecast (2024-2032)
  • 6.4 Clotting Factors
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2018-2023)
    • 6.4.3 Market Forecast (2024-2032)
  • 6.5 Fusion Protein
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2018-2023)
    • 6.5.3 Market Forecast (2024-2032)
  • 6.6 Others
    • 6.6.1 Historical and Current Market Trends (2018-2023)
    • 6.6.2 Market Forecast (2024-2032)

7 Japan Protein Therapeutics Market - Breakup by Therapy Area

  • 7.1 Metabolic Disorders
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2018-2023)
    • 7.1.3 Market Forecast (2024-2032)
  • 7.2 Immunological Disorders
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2018-2023)
    • 7.2.3 Market Forecast (2024-2032)
  • 7.3 Hematological Disorders
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2018-2023)
    • 7.3.3 Market Forecast (2024-2032)
  • 7.4 Cancer
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2018-2023)
    • 7.4.3 Market Forecast (2024-2032)
  • 7.5 Hormonal Disorders
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2018-2023)
    • 7.5.3 Market Forecast (2024-2032)
  • 7.6 Genetic Disorders
    • 7.6.1 Overview
    • 7.6.2 Historical and Current Market Trends (2018-2023)
    • 7.6.3 Market Forecast (2024-2032)
  • 7.7 Others
    • 7.7.1 Historical and Current Market Trends (2018-2023)
    • 7.7.2 Market Forecast (2024-2032)

8 Japan Protein Therapeutics Market - Breakup by Function

  • 8.1 Enzymatic and Regulatory Activity
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2018-2023)
    • 8.1.3 Market Forecast (2024-2032)
  • 8.2 Special Targeting Activity
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2018-2023)
    • 8.2.3 Market Forecast (2024-2032)
  • 8.3 Vaccines
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2018-2023)
    • 8.3.3 Market Forecast (2024-2032)
  • 8.4 Protein Diagnostics
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2018-2023)
    • 8.4.3 Market Forecast (2024-2032)

9 Japan Protein Therapeutics Market - Competitive Landscape

  • 9.1 Overview
  • 9.2 Market Structure
  • 9.3 Market Player Positioning
  • 9.4 Top Winning Strategies
  • 9.5 Competitive Dashboard
  • 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

  • 10.1 Company A
    • 10.1.1 Business Overview
    • 10.1.2 Product Portfolio
    • 10.1.3 Business Strategies
    • 10.1.4 SWOT Analysis
    • 10.1.5 Major News and Events
  • 10.2 Company B
    • 10.2.1 Business Overview
    • 10.2.2 Product Portfolio
    • 10.2.3 Business Strategies
    • 10.2.4 SWOT Analysis
    • 10.2.5 Major News and Events
  • 10.3 Company C
    • 10.3.1 Business Overview
    • 10.3.2 Product Portfolio
    • 10.3.3 Business Strategies
    • 10.3.4 SWOT Analysis
    • 10.3.5 Major News and Events
  • 10.4 Company D
    • 10.4.1 Business Overview
    • 10.4.2 Product Portfolio
    • 10.4.3 Business Strategies
    • 10.4.4 SWOT Analysis
    • 10.4.5 Major News and Events
  • 10.5 Company E
    • 10.5.1 Business Overview
    • 10.5.2 Product Portfolio
    • 10.5.3 Business Strategies
    • 10.5.4 SWOT Analysis
    • 10.5.5 Major News and Events

11 Japan Protein Therapeutics Market - Industry Analysis

  • 11.1 Drivers, Restraints, and Opportunities
    • 11.1.1 Overview
    • 11.1.2 Drivers
    • 11.1.3 Restraints
    • 11.1.4 Opportunities
  • 11.2 Porters Five Forces Analysis
    • 11.2.1 Overview
    • 11.2.2 Bargaining Power of Buyers
    • 11.2.3 Bargaining Power of Suppliers
    • 11.2.4 Degree of Competition
    • 11.2.5 Threat of New Entrants
    • 11.2.6 Threat of Substitutes
  • 11.3 Value Chain Analysis

12 Appendix